Immuno-Oncology Market

Global Market Study on Immuno-Oncology: Immune Checkpoint Inhibitors Segment Projected to be the Most Lucrative Segment by Therapy Type

Immuno-Oncology Market Segmented By Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Immune Checkpoint Inhibitors Therapy Type in Melanoma, Lung Cancer, Blood Cancers, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer Therapeutic Area

- Table of Content -

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusion and Exclusions

3. Market Dynamics

    3.1. Macro-Economic Factors

    3.2. Drivers

        3.2.1. Supply Side Drivers

        3.2.2. Demand Side Drivers

    3.3. Restraints

    3.4. Opportunities

    3.5. Trends

4. Key Inclusion

    4.1. Epidemiology Data, by Region

    4.2. Regulatory Scenario

    4.3. Patient Support Programs

    4.4. Pipeline Snapshot

5. Global Immuno-Oncology Market Value Analysis 2014-2018 and Forecast, 2019-2029

    5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018

    5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by Therapy

    6.1. Introduction / Key Findings

    6.2. Historical Market Size (US$ Mn) Analysis By Therapy, 2014-2018

    6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapy, 2019 - 2029

        6.3.1. Immune Checkpoint Inhibitors

            6.3.1.1. PD-1

            6.3.1.2. PD-L1

            6.3.1.3. CTLA-4

        6.3.2. Immune System Modulators

        6.3.3. Cancer Vaccines

        6.3.4. Oncolytic Virus

        6.3.5. Others (immune cell therapy, etc.)

    6.4. Market Attractiveness Analysis By Therapy

7. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by Therapeutic Area

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2014-2018

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Therapeutic Area, 2019 - 2029

        7.3.1. Melanoma

        7.3.2. Lung Cancer

        7.3.3. Blood Cancers

        7.3.4. Renal Cell Carcinoma

        7.3.5. Prostate Cancer

        7.3.6. Bladder Cancer

        7.3.7. Other Cancers

    7.4. Market Attractiveness Analysis By Therapeutic Area

8. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by End User

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By End User, 2014-2018

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2019 - 2029

        8.3.1. Hospitals

        8.3.2. Clinics

        8.3.3. Ambulatory Surgical Centers

    8.4. Market Attractiveness Analysis By End User

9. Global Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029, by Region

    9.1. Introduction

    9.2. Historical Market Size (US$ Mn) Analysis By Region, 2014-2018

    9.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2019 - 2029

        9.3.1. North America

        9.3.2. Latin America

        9.3.3. Europe

        9.3.4. Asia-Pacific

        9.3.5. Middle East & Africa

    9.4. Market Attractiveness Analysis By Region

10. North America Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

    10.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

        10.3.1. By Country

            10.3.1.1. U.S.

            10.3.1.2. Canada

        10.3.2. By Therapy

        10.3.3. By Therapeutic Area

        10.3.4. By End User

    10.4. Market Attractiveness Analysis

    10.5. Key Impact Analysis

11. Latin America Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

    11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

        11.3.1. By Country

            11.3.1.1. Brazil

            11.3.1.2. Mexico

            11.3.1.3. Rest of Latin America

        11.3.2. By Therapy

        11.3.3. By Therapeutic Area

        11.3.4. By End User

    11.4. Market Attractiveness Analysis

    11.5. Key Impact Analysis

12. Europe Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

        12.3.1. By Country

            12.3.1.1. Germany

            12.3.1.2. U.K.

            12.3.1.3. France

            12.3.1.4. Italy

            12.3.1.5. Spain

            12.3.1.6. Rest of Europe

        12.3.2. By Therapy

        12.3.3. By Therapeutic Area

        12.3.4. By End User

    12.4. Market Attractiveness Analysis

    12.5. Key Impact Analysis

13. Asia-Pacific Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

        13.3.1. By Country

            13.3.1.1. Japan

            13.3.1.2. South Korea

            13.3.1.3. Australia & New Zealand

            13.3.1.4. China

            13.3.1.5. Rest of Asia-Pacific

        13.3.2. By Therapy

        13.3.3. By Therapeutic Area

        13.3.4. By End User

    13.4. Market Attractiveness Analysis

    13.5. Key Impact Analysis

14. Middle East and Africa Immuno-Oncology Market Analysis 2014-2018 and Forecast 2019-2029

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014-2018

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2019-2029

        14.3.1. By Country

            14.3.1.1. GCC Countries

            14.3.1.2. South Africa

            14.3.1.3. Rest of MEA

        14.3.2. By Therapy

        14.3.3. By Therapeutic Area

        14.3.4. By End User

    14.4. Market Attractiveness Analysis

    14.5. Key Impact Analysis

15. Competition Analysis

    15.1. Company Share Analysis

    15.2. Competition Dashboard

    15.3. Competition Deep Dive

        15.3.1. Amgen, Inc.

            15.3.1.1. Company Overview

            15.3.1.2. Segment Overview

            15.3.1.3. TherapyOfferings

            15.3.1.4. Financial Analysis

            15.3.1.5. Key Developments

            15.3.1.6. Strategy Overview

        15.3.2. AstraZeneca Plc

            15.3.2.1. Company Overview

            15.3.2.2. Segment Overview

            15.3.2.3. TherapyOfferings

            15.3.2.4. Financial Analysis

            15.3.2.5. Key Developments

            15.3.2.6. Strategy Overview

        15.3.3. Bristol-Myers Squibb Company

            15.3.3.1. Company Overview

            15.3.3.2. Segment Overview

            15.3.3.3. TherapyOfferings

            15.3.3.4. Financial Analysis

            15.3.3.5. Key Developments

            15.3.3.6. Strategy Overview

        15.3.4. F. Hoffmann-La Roche Ltd.

            15.3.4.1. Company Overview

            15.3.4.2. Segment Overview

            15.3.4.3. TherapyOfferings

            15.3.4.4. Financial Analysis

            15.3.4.5. Key Developments

            15.3.4.6. Strategy Overview

        15.3.5. Merck & Co., Inc.

            15.3.5.1. Company Overview

            15.3.5.2. Segment Overview

            15.3.5.3. TherapyOfferings

            15.3.5.4. Financial Analysis

            15.3.5.5. Key Developments

            15.3.5.6. Strategy Overview

        15.3.6. Novartis AG

            15.3.6.1. Company Overview

            15.3.6.2. Segment Overview

            15.3.6.3. TherapyOfferings

            15.3.6.4. Financial Analysis

            15.3.6.5. Key Developments

            15.3.6.6. Strategy Overview

        15.3.7. Pfizer Inc.

            15.3.7.1. Company Overview

            15.3.7.2. Segment Overview

            15.3.7.3. TherapyOfferings

            15.3.7.4. Financial Analysis

            15.3.7.5. Key Developments

            15.3.7.6. Strategy Overview

        15.3.8. Sanofi.

            15.3.8.1. Company Overview

            15.3.8.2. Segment Overview

            15.3.8.3. TherapyOfferings

            15.3.8.4. Financial Analysis

            15.3.8.5. Key Developments

            15.3.8.6. Strategy Overview

16. Assumptions and Acronyms Used

17. Research Methodology

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

- List Of Table -

List of Tables

Table 01: Immuno-Oncology Market Value (US$ Mn) Growth Comparison

Table 02: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy

Table 03: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area

Table 04: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User

Table 05: Global Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Region

Table 06: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 07: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy

Table 08: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area

Table 09: North America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User

Table 10: Latin America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 11: Latin America Immuno-Oncology Market Size(US$Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy

Table 12: Latin America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area

Table 13: Latin America Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User

Table 14: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 15: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy

Table 16: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area

Table 17: Europe Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User

Table 18: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 19: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy

Table 20: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area

Table 21: Asia Pacific Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User

Table 22: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Country

Table 23: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapy

Table 24: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By Therapeutic Area

Table 25: Middle East and Africa Immuno-Oncology Market Size (US$ Mn) Analysis 2014–2018 and Forecast 2019–2029, By End User

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

- List Of Chart -

List of Figures

Figure 01: Global Immuno-Oncology Market Revenue Split by Therapy (2019)

Figure 02: Global Immuno-Oncology Market Revenue Split by Therapeutic Area (2019)

Figure 03: Global Immuno-Oncology Market Revenue Split by End User (2019)

Figure 04: Global Immuno-Oncology Market Revenue Split by Region (2019)

Figure 05: Global Immuno-Oncology Market Value Analysis (US$ Mn), 2014–2018

Figure 06: Global Immuno-Oncology Market Value Forecast (US$ Mn), 2019–2029

Figure 07: Global Immuno-Oncology Market Absolute $ Opportunity, 2019–2029

Figure 08: Comparison September 2017 and September 2019, Y-o-Y Forecast

Figure 09: Global Immuno-Oncology Market Share Analysis (%), By Therapy, 2019 & 2029

Figure 10: Global Immuno-Oncology Market Y-o-Y Analysis (%), By Therapy, 2019–2029

Figure 11: Global Immuno-Oncology Market Share Analysis (%), By Therapy, (2014-2018)

Figure 12: Global Immuno-Oncology Market Share Forecast (%), By Therapy, (2018-2029)

Figure 13: Global Immuno-Oncology Market Attractiveness Analysis By Therapy, 2019–2029

Figure 14: Global Immuno-Oncology Market Share Analysis (%), By Therapeutic Area, 2019 & 2029

Figure 15: Global Immuno-Oncology Market Y-o-Y Analysis (%), By Therapeutic Area, 2019–2029

Figure 16: Global Immuno-Oncology Market Share Analysis (%), By Therapeutic Area, (2014-2018)

Figure 17: Global Immuno-Oncology Market Share Forecast (%), By Therapeutic Area, (2018-2029)

Figure 18: Global Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2019–2029

Figure 19: Global Immuno-Oncology Market Share Analysis (%), By End User, 2019 & 2029

Figure 20: Global Immuno-Oncology Market Y-o-Y Analysis (%), By End User, 2019–2029

Figure 21: Global Immuno-Oncology Market Share Analysis (%), By End User, (2014-2018)

Figure 22: Global Immuno-Oncology Market Share Forecast (%), By End User, (2018-2029)

Figure 23: Global Immuno-Oncology Market Attractiveness Analysis By End User, 2019–2029

Figure 24: Global Immuno-Oncology Market Share Analysis (%), By Region, 2019 & 2029

Figure 25: Global Immuno-Oncology Market Y-o-Y Analysis (%), By Region, 2019–2029

Figure 26: Global Immuno-Oncology Market Share Analysis (%), By Region, (2014-2018)

Figure 27: Global Immuno-Oncology Market Share Forecast (%), By Region, (2018-2029)

Figure 28: Global Immuno-Oncology Market Attractiveness Analysis By Region, 2019–2029

Figure 29: North America Immuno-Oncology Market Value Share, By Therapy, 2019 (E)

Figure 30: North America Immuno-Oncology Market Value Share, By Therapeutic area, 2019 (E)

Figure 31: North America Immuno-Oncology Market Value Share, By End User, 2019 (E)

Figure 32: North America Immuno-Oncology Market Value Share, By Country, 2019 (E)

Figure 33: North America Immuno-Oncology Market Value Analysis (US$ Mn), 2014–2018

Figure 34: North America Immuno-Oncology Market Value Forecast (US$ Mn), 2019–2029

Figure 35: North America Immuno-Oncology Market Attractiveness Analysis By Therapy, 2019–2029

Figure 36: North America Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2019–2029

Figure 37: North America Immuno-Oncology Market Attractiveness Analysis By End User, 2019–2029

Figure 38: North America Immuno-Oncology Market Attractiveness Analysis By Country, 2019–2029

Figure 39: Latin America Immuno-Oncology Market Value Share, By Therapy, 2019 (E)

Figure 40: Latin America Immuno-Oncology Market Value Share, By Therapeutic area, 2019 (E)

Figure 41: Latin America Immuno-Oncology Market Value Share, By End User, 2019 (E)

Figure 42: Latin America Immuno-Oncology Market Value Share, By Country, 2019 (E)

Figure 43: Latin America Immuno-Oncology Market Value Analysis (US$ Mn), 2014–2018

Figure 44: Latin America Immuno-Oncology Market Value Forecast (US$ Mn), 2019–2029

Figure 45: Latin America Immuno-Oncology Market Attractiveness Analysis By Therapy, 2019–2029

Figure 46: Latin America Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2019–2029

Figure 47: Latin America Immuno-Oncology Market Attractiveness Analysis By End User, 2019–2029

Figure 48: Latin America Immuno-Oncology Market Attractiveness Analysis By Country, 2019–2029

Figure 49: Europe Immuno-Oncology Market Value Share, By Therapy, 2019 (E)

Figure 50: Europe Immuno-Oncology Market Value Share, By Therapeutic area, 2019 (E)

Figure 51: Europe Immuno-Oncology Market Value Share, By End User, 2019 (E)

Figure 52: Europe Immuno-Oncology Market Value Share, By Country, 2019 (E)

Figure 53: Europe Immuno-Oncology Market Value Analysis (US$ Mn), 2014–2018

Figure 54: Europe Immuno-Oncology Market Value Forecast (US$ Mn), 2019–2029

Figure 55: Europe Immuno-Oncology Market Attractiveness Analysis By Therapy, 2019–2029

Figure 56: Europe Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2019–2029

Figure 57: Europe Immuno-Oncology Market Attractiveness Analysis By End User, 2019–2029

Figure 58: Europe Immuno-Oncology Market Attractiveness Analysis By Country, 2019–2029

Figure 59: Asia Pacific Immuno-Oncology Market Value Share, By Therapy, 2019 (E)

Figure 60: Asia Pacific Immuno-Oncology Market Value Share, By Therapeutic area, 2019 (E)

Figure 61: Asia Pacific Immuno-Oncology Market Value Share, By End User, 2019 (E)

Figure 62: Asia Pacific Immuno-Oncology Market Value Share, By Country, 2019 (E)

Figure 63: Asia Pacific Immuno-Oncology Market Value Analysis (US$ Mn), 2014–2018

Figure 64: Asia Pacific Immuno-Oncology Market Value Forecast (US$ Mn), 2019–2029

Figure 65: Asia Pacific Immuno-Oncology Market Attractiveness Analysis By Therapy, 2019–2029

Figure 66: Asia Pacific Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2019–2029

Figure 67: Asia Pacific Immuno-Oncology Market Attractiveness Analysis By End User, 2019–2029

Figure 68: Asia Pacific Immuno-Oncology Market Attractiveness Analysis By Country, 2019–2029

Figure 69: MEA Immuno-Oncology Market Value Share, By Therapy, 2019 (E)

Figure 70: MEA Immuno-Oncology Market Value Share, By Therapeutic area, 2019 (E)

Figure 71: MEA Immuno-Oncology Market Value Share, By End User, 2019 (E)

Figure 72: MEA Immuno-Oncology Market Value Share, By Country, 2019 (E)

Figure 73: Middle East and Africa Immuno-Oncology Market Value Analysis (US$ Mn), 2014–2018

Figure 74: Middle East and Africa Immuno-Oncology Market Value Forecast (US$ Mn), 2019–2029

Figure 75: Middle East and Africa Immuno-Oncology Market Attractiveness Analysis By Therapy, 2019–2029

Figure 76: Middle East and Africa Immuno-Oncology Market Attractiveness Analysis By Therapeutic Area, 2019–2029

Figure 77: Middle East and Africa Immuno-Oncology Market Attractiveness Analysis By End User, 2019–2029

Figure 78: Middle East and Africa Immuno-Oncology Market Attractiveness Analysis By Country, 2019–2029

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate